AstraZeneca shares fall about 1.3% after positive Phase 3 COPD results
AstraZeneca fell about 1.3% to $158 Wednesday, after its experimental COPD treatment reported positive Phase 3 results.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.